| Affiliation: | 1. University of North Carolina Medical Center, Chapel Hill, North Carolina, USA;2. University of Rochester Medical Center, Rochester, New York, USA;3. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;4. MD Anderson Cancer Center at Cooper, Camden, New Jersey, USA;5. Langone Medical Center, New York University, New York City, New York, USA;6. Florida Cancer Specialists and Research Institute, Sarasota, Florida, USA;7. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA;8. Department of Urology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA |
| Abstract: | Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (p = .21), corresponding to an odds ratio for pT0 of 0.45 (95% CI, 0.16–1.31) with SS cisplatin. Split schedule cisplatin was associated with numerically but not statistically significant lower pathologic response rates relative to full dose. |
